Hydrochlorothiazide 25 mg Tablet, 1,000-count
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Thiazide Diuretic class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- It's a water pill — a diuretic — that helps your kidneys flush out extra salt and water. This lowers your blood pressure and reduces swelling (edema) caused by conditions like hear...
- What exactly is hydrochlorothiazide supposed to do for me?
- Most people take it once daily in the morning — that way the extra trips to the bathroom happen during the day, not overnight. Taking it with food slightly reduces how much your bo...
- When should I take it, and does it matter if I take it with food?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Hydrochlorothiazide — tap one for details:
Hydrochlorothiazide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.012 | $11.70 / 1000 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.1406 | $140.60 / 1000 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.0822 | $82.20 / 1000 tablets |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg 00172-2083-60 | Teva | 100 tablets | $0.012 | AB | Availability likely | — |
| Hydrochlorothiazide 25 mg 16729-0183-01 | Accord | 100 tablets | $0.012 | AB | Availability likely | — |
| Hydrochlorothiazide 25 mg 23155-0008-01 | Heritage | 100 tablets | $0.012 | AB | Availability likely | — |
| Hydrochlorothiazide 25 mg 29300-0128-01 | Unichem | 100 tablets | $0.012 | AB | Availability likely | — |
| Hydrochlorothiazide 25 mg 60687-0593-01 | American | 100 tablets | $0.012 | — | Availability likely | — |
| Hydrochlorothiazide 25 mg 60687-0894-01 | American | 100 tablets | $0.012 | AB | Availability likely | — |
| Hydrochlorothiazide 25 mg 62135-0448-05 | Chartwell | 500 tablets | $0.012 | AB | Availability likely | — |
| Hydrochlorothiazide 25 mg 68645-0510-54 | Legacy | 30 tablets | $0.012 | AB | Availability likely | — |
| Hydrochlorothiazide 25 mg 69315-0131-01 | Leading | 100 tablets | $0.012 | AB | Availability likely | — |
| Hydrochlorothiazide 25 mgthis 69584-0361-90 | Oxford | 1000 tablets | $0.012 | AB | Availability likely | — |
| Hydrochlorothiazide 25 mg 00615-8450-05 | NCS | 15 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 42708-0028-30 | QPharma, | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 42708-0079-30 | QPharma, | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 42708-0164-30 | QPharma | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 43353-0719-15 | Aphena | 15 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 43547-0397-01 | Solco | 10 tablets | — | — | FDA listed | — |
| Hydrochlorothiazide 25 mg 50090-0140-00 | A-S | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 50090-0141-00 | A-S | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 50090-5057-00 | A-S | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 50090-5333-00 | A-S | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 50090-6014-00 | A-S | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 50090-6157-00 | A-S | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 50090-6158-00 | A-S | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 50090-6160-00 | A-S | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 50228-0111-10 | ScieGen | 1000 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 51407-0331-01 | Golden | 100 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 51655-0088-52 | Northwind | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 51655-0272-26 | Northwind | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 51655-0515-26 | Northwind | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 51655-0831-26 | Northwind | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 55700-0006-30 | Lake | 30 tablets | — | AB | Discontinued | — |
| Hydrochlorothiazide 25 mg 60760-0315-30 | St. | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 63187-0367-00 | Proficient | 100 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 63187-0440-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 63629-1218-01 | Bryant | 100 tablets | — | — | FDA listed | — |
| Hydrochlorothiazide 25 mg 65862-0133-01 | Aurobindo | 100 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 66267-0106-30 | NuCare | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 67296-2043-03 | Redpharm | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 68071-2411-01 | NuCare | 20 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 68071-4819-01 | NuCare | 100 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 68071-4933-07 | NuCare | 20 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 68071-4963-09 | NuCare | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 68071-5211-02 | NuCare | 120 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 68788-8517-00 | Preferred | 100 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 70518-3633-00 | REMEDYREPACK | 30 tablets | — | AB | Discontinued | — |
| Hydrochlorothiazide 25 mg 70518-3749-00 | REMEDYREPACK | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 70518-4113-00 | REMEDYREPACK | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 70518-4359-00 | REMEDYREPACK | 15 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 71205-0419-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 71205-0793-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 71335-0269-00 | Bryant | 120 tablets | — | AB | Discontinued | — |
| Hydrochlorothiazide 25 mg 71335-0652-00 | Bryant | 8 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 71335-1481-00 | Bryant | 120 tablets | — | — | FDA listed | — |
| Hydrochlorothiazide 25 mg 71610-0488-15 | Aphena | 15 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 72789-0296-30 | PD-Rx | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 72789-0381-90 | PD-Rx | 90 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 72789-0512-30 | PD-Rx | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 76282-0154-01 | Exelan | 100 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 82804-0972-00 | Proficient | 100 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 87441-0038-01 | Unit | 30 tablets | — | AB | FDA listed | — |
| Hydrochlorothiazide 25 mg 67296-2280-09 | Redpharm | 90 tablets | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 69584-0361-10 | 100 TABLET in 1 BOTTLE (69584-361-10) | $0.0117 / ea | $1.17 | 2020-09-25 | Active |
| 69584-0361-90 You're viewing this | 1000 TABLET in 1 BOTTLE (69584-361-90) | $0.0117 / ea | $11.65 | 2020-09-25 | Active |
| 69584-0361-95 | 5000 TABLET in 1 BOTTLE (69584-361-95) | $0.0117 / ea | $58.25 | 2020-09-25 | Active |
You're viewing one of 3 pack sizes for this product.
This pack effectively ties for the lowest per-ea cost of the 3 priced pack sizes ($0.0117 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 94% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 69584-0361-90?
What is the difference between NDC 69584-0361-90 and NDC 69584-0361-10?
What NDC number is used to bill for this package of Hydrochlorothiazide 25 mg Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
⏱️ Dosage and Administration ▾
Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response. Adults For Edema The usual adult dosage is 25 to 100 mg daily as a single or divided dose.
Many patients with edema respond to intermittent therapy, i.e., administration on alternate days or on three to five days each week. With an intermittent schedule, excessive response and the resulting undesirable electrolyte imbalance are less likely to occur. For Control of Hypertension The usual initial dose in adults is 25 mg daily given as a single dose.
The dose may be increased to 50 mg daily, given as a single or two divided doses. Doses above 50 mg are often associated with marked reductions in serum potassium (see also PRECAUTIONS ). Patients usually do not require doses in excess of 50 mg of hydrochlorothiazide daily when used concomitantly with other antihypertensive agents.
Infants and Children For Diuresis and for Control of Hypertension The usual pediatric dosage is 0.5 to 1 mg per pound (1 to 2 mg/kg) per day in single or two divided doses, not to exceed 37.5 mg per day in infants up to 2 years of age or 100 mg per day in children 2 to 12 years of age. In infants less than 6 months of age, doses up to 1.5 mg per pound (3 mg/kg) per day in two divided doses may be required (see PRECAUTIONS, Pediatric Use ). HOW SUPPLIED
⛔ Contraindications ▾
CONTRAINDICATIONS Anuria. Hypersensitivity to this product or to other sulfonamide-derived drugs
⚠️ Warnings ▾
WARNINGS Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.
Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Thiazides may add to or potentiate the action of other antihypertensive drugs. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma.
The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. Lithium generally should not be given with diuretics (see PRECAUTIONS, Drug Interactions ). Acute Myopia and Secondary Angle-Closure Glaucoma Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma.
Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible.
Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle- closure glaucoma may include a history of sulfonamide or penicillin allergy.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity. Body as a Whole Weakness. Cardiovascular Hypotension including orthostatic hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs).
Digestive Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia. Hematologic Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia. Hypersensitivity Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura.
Metabolic Electrolyte imbalance (see PRECAUTIONS) , hyperglycemia, glycosuria, hyperuricemia. Musculoskeletal Muscle spasm. Nervous System/Psychiatric Vertigo, paresthesias, dizziness, headache, restlessness.
Renal Renal failure, renal dysfunction, interstitial nephritis (see WARNINGS ). Skin Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia. Special Senses Transient blurred vision, xanthopsia.
Urogenital Impotence. Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn. Postmarketing Experience Non-melanoma Skin Cancer Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer.
In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of ≥50,000 mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.
🔄 Drug Interactions ▾
Drug Interactions When given concurrently the following drugs may interact with thiazide diuretics. Alcohol, Barbiturates, or Narcotics Potentiation of orthostatic hypotension may occur. Antidiabetic Drugs (Oral Agents and Insulin) Dosage adjustment of the antidiabetic drug may be required.
Other Antihypertensive Drugs Additive effect or potentiation. Cholestyramine and Colestipol Resins Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.
Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. Pressor Amines (e.g., Norepinephrine) Possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal Muscle Relaxants, Nondepolarizing (e.g., Tubocurarine) Possible increased responsiveness to the muscle relaxant.
Lithium Generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with hydrochlorothiazide.
Nonsteroidal Anti-Inflammatory Drugs In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained. Drug/Laboratory Test Interactions
🔄 Drug / Laboratory Test Interactions ▾
Thiazides should be discontinued before carrying out tests for parathyroid function (see PRECAUTIONS, Genera l ). Carcinogenesis, Mutagenesis, Impairment of Fertility
👥 Use in Specific Populations ▾
Use in Pregnancy Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy.
Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary.
During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief.
Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate.
🤰 Pregnancy ▾
Pregnancy Teratogenic Effects Studies in which hydrochlorothiazide was orally administered to pregnant mice and rats during their respective periods of major organogenesis at doses up to 3000 and 1000 mg hydrochlorothiazide/kg, respectively, provided no evidence of harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nonteratogenic Effects hiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults. Nursing Mothers
🆘 Overdosage ▾
OVERDOSAGE The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. In the event of overdosage, symptomatic and supportive measures should be employed.
Emesis should be induced or gastric lavage performed. Correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment.
The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD 50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat. DOSAGE AND ADMINISTRATION
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY The mechanism of the antihypertensive effect of thiazides is unknown. Hydrochlorothiazide does not usually affect normal blood pressure. Hydrochlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption.
At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.
After oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours. Pharmacokinetics and Metabolism Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.
At least 61 percent of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk. INDICATIONS AND USAGE Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Hydrochlorothiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard.
Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ).
Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease.
However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest.
In these instances, a short course of diuretic therapy may provide relief and be appropriate.
📦 How Supplied / Storage and Handling ▾
Hydrochlorothiazide Tablets, USP are supplied as follows: 25 mg - Peach, round scored tablets, upper debossed with "361" above bisect and lower debossed "O". Available in bottles of: 100, NDC 69584-361-10 1000, NDC 69584-361-90 5000, NDC 69584-361-95 50 mg - Peach, round scored tablets, upper debossed with "362" above bisect and lower debossed "O". Available in bottles of: 100, NDC 69584-362-10 1000, NDC 69584-362-90.
Store at: 20-25°C (68-77°F). [See USP Controlled Room Temperature]. Dispense in a well-closed container as defined in the USP, with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
Manufactured by: Oxford Pharmaceuticals, LLC Birmingham, Alabama 35211 8200020 Revised: 12/2024 R01
📋 Description ▾
DESCRIPTION Hydrochlorothiazide, USP is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. Its chemical name is 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide, and its structural formula is C 7 H 8 ClN 3 O 4 S 2 M.W.
297.74 Hydrochlorothiazide, USP is a white, or practically white, crystalline powder, which is slightly soluble in water, but freely soluble in sodium hydroxide solution. Each tablet for oral administration contains 25 mg or 50 mg hydrochlorothiazide, USP. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, pregelatinized starch from corn, magnesium stearate, microcrystalline cellulose, and FD&C Yellow #6.
💬 Information for Patients ▾
Information for Patients Non-melanoma Skin Cancer: Instruct patients taking hydrochlorothiazide to protect skin from the sun and undergo regular skin cancer screening.
There are no well controlled clinical trials in pediatric patients. Information on dosing in this age group is supported by evidence from empiric use in pediatric patients and published literature regarding the treatment of hypertension in such patients (see DOSAGE AND ADMINISTRATION, Infants and Children ).